Podcast appearances and mentions of Jared S Hopkins

The price Medicare pays for a single medicine can range by thousands of dollars, even for people enrolled in the same plan. Wall Street Journal health and science reporter Jared S. Hopkins joins host J.R. Whalen to discuss why this happens. Sign up for the WSJ's free Markets A.M. newsletter.  Learn more about your ad choices. Visit megaphone.fm/adchoices

Scientists are looking at animal data to improve the speed of some medical test results. They're taking that data, building artificial intelligence tools and then using those tools to train diagnostic algorithms for humans. WSJ pharmaceuticals reporter Jared S. Hopkins joins host Julie Chang to explain how this tech works and which companies are involved. Learn more about your ad choices. Visit megaphone.fm/adchoices

Congress returns from its summer recess with a long list of tasks and only a few work days to get them done. On top of the annual spending bills needed to keep the government operating, on the list are bills to renew the global HIV/AIDS program, PEPFAR, and the community health centers program. Meanwhile, over the recess, the Biden administration released the names of the first 10 drugs selected for the Medicare price negotiation program. Alice Miranda Ollstein of Politico, Rachel Cohrs of Stat, and Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico join KFF Health News chief Washington correspondent Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Meena Seshamani, who leads the federal Medicare program, about how the drug price negotiation program will work. Plus, for “extra credit,” the panelists suggest health policy stories they read this week they think you should read, too: Julie Rovner: JAMA Health Forum's “Health Systems and Social Services — A Bridge Too Far?” by Sherry Glied and Thomas D'Aunno. Alice Miranda Ollstein: The Washington Post's “Heat's Hidden Risk,” by Shannon Osaka, Erin Patrick O'Connor, and John Muyskens. Rachel Cohrs: The Wall Street Journal's “How Novartis's CEO Learned From His Mistakes and Got Help From an Unlikely Quarter,” by Jared S. Hopkins. Joanne Kenen: Politico's “How to Wage War on Conspiracy Theories,” by Joanne Kenen, and “Court Revives Doctors' Lawsuit Saying FDA Overstepped Its Authority With Anti-Ivermectin Campaign,” by Kevin McGill. Click here for a transcript of the episode. Hosted on Acast. See acast.com/privacy for more information.

This week, the U.S. government named 10 drugs that will be subject to the first ever price negotiations by Medicare. WSJ's Jared S. Hopkins talks about how this major change came about and pharmaceutical companies' efforts to stop it. Further Listening: -How Big Pharma Lost Its Swagger  Further Reading: -Expensive Drugs From Pfizer, Other Companies Targeted for First U.S. Price Negotiations  -U.S. Chamber of Commerce Challenges Federal Government's New Drug-Price Powers  -Merck Challenges U.S. Government's New Powers to Negotiate Drug Prices  Learn more about your ad choices. Visit megaphone.fm/adchoices

P.M. Edition for Aug. 29. Hurricane Idalia has strengthened as it heads toward Florida. Deborah Acosta reports from Tampa. Plus, the U.S. government names ten drugs it's targeting in the first-ever price negotiations by Medicare. Pharmaceutical reporter Jared S. Hopkins explains what the talks could mean for consumers. And Grayscale wins a court battle with the SEC, raising hopes for the first bitcoin exchange-traded fund. Annmarie Fertoli hosts. Learn more about your ad choices. Visit megaphone.fm/adchoices

Pharmaceutical giant Merck has developed a drug against Covid, the first treatment that wouldn't require hospitalization. But WSJ's Jared S. Hopkins tells us distributing it equitably around the world will be a challenge. Learn more about your ad choices. Visit megaphone.fm/adchoices

It's been a long month since the last bonus Thank You episode! In this episode, get an update on the ongoing regime change operation in Belarus and find out why the vaccine intellectual property waiver actually has a chance of becoming a reality. After those updates, Jen responds to a lot of notes from producers. Thanks for supporting the show! Please Support Congressional Dish – Quick Links Click here to contribute monthly or a lump sum via PayPal Click here to support Congressional Dish for each episode via Patreon Send Zelle payments to: Donation@congressionaldish.com Send Venmo payments to: @Jennifer-Briney Send Cash App payments to: $CongressionalDish or Donation@congressionaldish.com Use your bank's online bill pay function to mail contributions to: 5753 Hwy 85 North, Number 4576, Crestview, FL 32536 Please make checks payable to Congressional Dish Thank you for supporting truly independent media! Recommended Congressional Dish Episodes CD229: Target Belarus CD233: Long COVID CDTY: Thank You Alcee Articles/Documents Article: World Bank opposes vaccine IP waiver The Bull, June 17, 2021 Article: Pfizer, Moderna vaccines now preferred second dose for AstraZeneca recipients: NACI by Mia Rabson, The Canadian Press, North Shore News, June 17, 2021 Article: Delta COVID-19 variant is now in more than 80 countries, WHO says By Emily Shapiro, ABC News, June 17, 2021 Article: Delta variant causes more than 90% of new Covid cases in UK By Nicola Davis, The Guardian, June 11, 2021 Statement: FACT SHEET: President Biden Announces Historic Vaccine Donation: Half a Billion Pfizer Vaccines to the World's Lowest-Income Nations The Bull, June 10, 2021 Article: World Bank opposes vaccine IP waiver The Bull, June 8, 2021 Article: US contributed USD 2 billion to GAVI for COVAX facility Malaysia Sun, June 5, 2021 Article: Why Joe Biden Punched Big Pharma in the Nose Over Covid Vaccines by Matt Stoller, May 9, 2021 Article: U.S. Backs Waiver of Intellectual Property Protection for Covid-19 Vaccines By Yuka Hayashi and Jared S. Hopkins, The Wall Street Journal, May 6, 2021 Article: Pharma loses vaccine IP battle despite record Q1 lobbying By Alyce McFadden, Opensecrets.org, May 4, 2021 Article: Government-Funded Scientists Laid the Groundwork for Billion-Dollar Vaccines by Arthur Allen, KHN, November 18, 2020 Sound Clip Sources Hearing: U.S. Policy on Belarus Senate Foreign Relations Committee, June 9, 2021 Watch on CSPAN Witnesses Julie Fisher: US Ambassador to Belarus Sviatlana Tsikhaouskaya: Want-to-be President of Belarus Jamie Fly: President and CEO of Radio Free Liberty/Radio Liberty Transcript: 2:45 - Sen. Bob Menendez (NJ) confirms that Senators Rob Portman (OH), Jeanne Shaheen (NH), and Chris Murphy (CT) all traveled to visit the people trying to change the government of Belarus in early June. 14:30 - Julie Fisher confirms that more sanctions are imminent 30:40 - Sen. Rob Portman's (OH) main takeaway from his visit is that Belarus's military partnership with Russia threatens Ukraine 1:35:00 - Julie Fisher confirms that U.S. diplomats access to Belarus will be limited Cover Art Design by Only Child Imaginations Music Presented in This Episode Intro & Exit: Tired of Being Lied To by David Ippolito (found on Music Alley by mevio)

P.M. Edition for Oct. 21. As the world waits for coronavirus vaccines, authorities are taking extreme measures to protect initial doses from thieves. Pharmaceutical reporter Jared S. Hopkins joins host Annmarie Fertoli with more details. Learn more about your ad choices. Visit megaphone.fm/adchoices

P.M. Edition for Sept. 8. Amid concerns over the rapid pace of Covid-19 vaccine development, nine drugmakers including Pfizer, AstraZeneca and Moderna say they won't rush to seek approval for a vaccine until it proves safe and effective in a late-stage trial. Pharmaceutical reporter Jared S. Hopkins joins host Annmarie Fertoli with more details. Learn more about your ad choices. Visit megaphone.fm/adchoices

The Game Plan to What’s NextWe are moving in the right direction with the virus and can see great strides in the economy to recover.Counting drugs approved for other diseases, there are 254 clinical trials testing treatments or vaccines for the virus, many spearheaded by universities and government research agencies, with hundreds more trials planned. Researchers have squeezed timelines that usually total months into weeks or even days.“We have never gone so fast with so many resources in such a short time frame,” said Paul Stoffels, chief scientific officer of Johnson & Johnson.Joseph Walker, Peter Loftus and Jared S. Hopkins WSJ